MOCRAVIMOD DOES NOT HAVE A CLINICALLY RELEVANT DRUG-DRUG INTERACTION WITH STRONG CYP3A4 INHIBITOR ITRACONAZOLE

被引：0
|
作者：
Huntjens, Dymphy [1 ]
Oehen, Stephan [1 ]
Kueenburg, Elisabeth [1 ]
机构：
[1] Priothera SAS, St Louis, France
来源：
BONE MARROW TRANSPLANTATION | 2024年 / 59卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P768
引用
收藏
页码：740 / 741
页数：2
相关论文
共 50 条
  • [21] A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling
    Fuhr, Laura Maria
    Marok, Fatima Zahra
    Mees, Maximilian
    Mahfoud, Felix
    Selzer, Dominik
    Lehr, Thorsten
    PHARMACEUTICS, 2022, 14 (07)
  • [22] Rationally Engineered CYP3A4 Fluorogenic Substrates for Functional Imaging Analysis and Drug-Drug Interaction Studies
    He, Rong-Jing
    Tian, Zhen-Hao
    Huang, Jian
    Sun, Meng-Ru
    Wei, Feng
    Li, Chun-Yu
    Zeng, Hai-Rong
    Zhang, Feng
    Guan, Xiao-Qing
    Feng, Yan
    Meng, Xiang-Ming
    Yang, Hui
    Ge, Guang-Bo
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (10) : 6743 - 6755
  • [23] Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
    Neuvonen, PJ
    Kantola, T
    Kivistö, KT
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (03) : 332 - 341
  • [24] CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions
    Galetin, A
    Ito, K
    Hallifax, D
    Houston, JB
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 314 (01): : 180 - 190
  • [25] The impact of CYP3A4 genetic polymorphism on crizotinib metabolism and drug-drug interactions
    Wang, Jing
    Xu, Xiao-yu
    Li, Xin-yue
    Luo, Jian-chao
    Zhang, Zhe-yan
    Chen, Jing
    Cai, Jian-ping
    Zhang, Li-kang
    Qian, Jian-chang
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2024, 489
  • [26] In vitro interactions of abiraterone, erythromycin, and CYP3A4: implications for drug-drug interactions
    Masamrekh, Rami A.
    Kuzikov, Alexey V.
    Haurychenka, Yaraslau I.
    Shcherbakov, Kirill A.
    Veselovsky, Alexander V.
    Filimonov, Dmitrii A.
    Dmitriev, Alexander V.
    Zavialova, Maria G.
    Gilep, Andrei A.
    Shkel, Tatsiana V.
    Strushkevich, Natallia V.
    Usanov, Sergey A.
    Archakov, Alexander I.
    Shumyantseva, Victoria V.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2020, 34 (01) : 120 - 130
  • [27] Drug-Drug Interactions between Atorvastatin and Dronedarone Mediated by Monomeric CYP3A4
    Denisov, Ilia G.
    Baylon, Javier L.
    Grinkova, Yelena V.
    Tajkhorshid, Emad
    Sligar, Stephen G.
    BIOCHEMISTRY, 2018, 57 (05) : 805 - 816
  • [28] Pharmacokinetic drug-drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate
    Winkler, Julia
    Goldammer, Mark
    Ludwig, Matthias
    Rohde, Beate
    Zurth, Christian
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2015, 40 (04) : 389 - 399
  • [29] Drug-Drug Interaction Studies to Evaluate the Effect of Inhibition of UGT1A1 and CYP3A4 and Induction of CYP3A4 on the Pharmacokinetics of Tropifexor in Healthy Subjects
    Chen, Jin
    Stringer, Rowan
    Shah, Bharti
    Gu, Jessie
    Zhang, Yiming
    Hackling, Melissa
    Prince, William
    Woessner, Ralph
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (11): : 1253 - 1263
  • [30] Clinically relevant bidirectional drug-drug interaction between midostaurin and voriconazole
    Haefliger, David
    Marzolini, Catia
    Lamoth, Frederic
    Pabst, Thomas
    Buclin, Thierry
    Livio, Francoise
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (07) : 2304 - 2308
12345